Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Inclusion Criteria:

1. Male or female participants ≥18 years of age.

2. History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], orperipheral arterial disease [PAD]).

3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).

4. Fasting triglyceride <4.52 mmol/L (<400 mg/dL) at screening.

5. Participants on statins should be receiving a maximally tolerated dose.

6. Participants not receiving statins must have documented evidence of intolerance to alldoses of at least 2 different statins.

7. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on astable dose for ≥30 days before screening with no planned medication or dose changeduring study participation.

Exclusion Criteria:

1. New York Heart Association (NYHA) class IV heart failure.

2. Uncontrolled cardiac arrhythmia

3. Uncontrolled severe hypertension

4. Active liver disease

5. Females who are pregnant or nursing, or who are of childbearing potential andunwilling to use at least 2 methods of highly effective contraception (failure rateless than 1% per year) (for example, combined oral contraceptives, barrier methods,approved contraceptive implant, long-term injectable contraception, or intrauterinedevice) for the entire duration of the study. Exemptions from this criterion:

6. Women >2 years postmenopausal (defined as 1 year or longer since last menstrualperiod) and more than 55 years of age.

7. Postmenopausal women (as defined above) and less than 55 years of age with anegative pregnancy test within 24 hours of randomization.

8. Women who are surgically sterilized at least 3 months prior to enrollment.

9. Males who are unwilling to use an acceptable method of birth control during the entirestudy period (such as condom with spermicide).

10. Treatment with other investigational products or devices within 30 days or 5half-lives of the screening visit, whichever is longer.

11. Treatment (within 90 days of screening) with monoclonal antibodies directed towardsPCSK9 The above information is not intended to contain all considerations relevant to aparticipant's potential participation in a clinical trial.